SynAct Pharma has signed a contract with a CRO and aims to submit a Clinical Trial Application this quarter for the upcoming clinical phase IIb study with resomelagon. Furthermore, the company has conducted a capital raise of SEK 49 million, and the new board and management team are working to reduce costs.
- Together, the new team is more focused and ready to move fast, says CEO Jeppe Øvlesen. 

Read the full article at biostock.se:

https://www.biostock.se/en/2024/05/synact-pharmas-ceo-provides-an-update/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/synact/r/biostock-synact-pharma-s-ceo-provides-an-update,c3971958

(c) 2024 Cision. All rights reserved., source Press Releases - English